Novo Nordisk’s Semaglutide fails to slow Alzheimer’s progression in Phase 3 trials

The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years

EMA launches streamlined process to fast-track critical medicines, vaccines

The move is expected to be crucial during health crises

Ingenus Pharma launches first FDA-approved generic version of Premarin

Conjugated Estrogens Tablets are indicated for moderate to severe menopausal symptoms, including hot flashes, and for the prevention of postmenopausal osteoporosis in women at significant risk

EMA recommends authorization of Teizeild to delay Type 1 diabetes onset

This is the first drug to receive a recommendation for this preventative indication in the European Union

Merck KGaA Q3 2025 net sales remains flat amid geopolitical uncertainty

Biotronik selects Syensqo’s Eviva Polysulfone for pacemaker header components

The high-performance polymer’s transparency and biocompatibility support precise implantation and long-term reliability

Novo Nordisk presents four new analyses on oral semaglutide 25 mg at ObesityWeek 2025

Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively

Effective corrosion management demands a holistic approach: Experts

From material selection to cooling tower management, every small decision affects long-term equipment reliability

Zydus Wellness appoints Manish Lal as Head, Global Demand and Supply Organization

With over two decades of extensive experience, Lal has established himself as a transformational leader in the FMCG and consumer goods sectors

Roche presents positive phase III data for vamikibart in uveitic macular edema

Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME